{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:25:43Z","timestamp":1749853543149},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T00:00:00Z","timestamp":1405382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"US Public Health Service","award":["DK056033"],"award-info":[{"award-number":["DK056033"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,9]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Little is known regarding patient characteristics that influence the speed of reflux oesophagitis (RO<\/jats:styled-content>) healing.<\/jats:p><\/jats:sec>Aim<\/jats:title>To investigate patient characteristics that may influence RO<\/jats:styled-content> healing rates.<\/jats:p><\/jats:sec>Methods<\/jats:title>A post hoc<\/jats:italic> analysis of clinical trial data for potent acid suppression treatment of RO<\/jats:styled-content> (esomeprazole or <\/jats:italic>AZD<\/jats:styled-content>0865) was conducted. Group A underwent endoscopy at baseline, week 2 and 4, and group B at baseline, week 4 and 8. Group A patients were sub\u2010grouped as \u2018rapid\u2019 (healed at 2\u00a0weeks) or unhealed at 2\u00a0weeks. Group B patients were sub\u2010grouped as \u2018slow\u2019 (healed at 8\u00a0weeks, not at 4\u00a0weeks) or \u2018refractory\u2019 (not healed at 8\u00a0weeks). Logistic regression analysis was performed only for comparisons within group A.<\/jats:p><\/jats:sec>Results<\/jats:title>At 2, 4 and 8\u00a0weeks, RO<\/jats:styled-content> had healed in 68%, 65% and 61% of patients unhealed at previous endoscopy, respectively. Low\u2010grade [vs. high\u2010grade (C or D)] RO<\/jats:styled-content> was the only independent predictor of rapid healing in group A after logistic regression analysis. Significantly more rapid healers had low grade RO<\/jats:styled-content> (A or B) at baseline than patients with refractory RO<\/jats:styled-content> (84% vs. 49%; P\u00a0<\/jats:italic><\u00a0<\/jats:italic>0.001), and significantly more refractory patients had frequent regurgitation at baseline than slow healers (80% vs. 63%; P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.039).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Low\u2010 (vs. high\u2010) grade RO<\/jats:styled-content> determines the most rapid benefit from acid suppression. Roughly two\u2010thirds of patients healed with each time increment of potent acid suppression therapy. This suggests that some unhealed patients may still heal with continued therapy and that truly refractory RO<\/jats:styled-content> is rare. (ClinicalTrials.gov: NCT<\/jats:styled-content>00206245).<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12877","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T19:25:20Z","timestamp":1405452320000},"page":"648-656","source":"Crossref","is-referenced-by-count":6,"title":["Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression"],"prefix":"10.1111","volume":"40","author":[{"given":"P. J.","family":"Kahrilas","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Feinberg School of Medicine Northwestern University Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Persson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Denison","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wernersson","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D M\u00f6lndal Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Research Evaluation Unit Oxford PharmaGenesis Ltd Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. W.","family":"Howden","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Feinberg School of Medicine Northwestern University Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.172"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03235.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03074.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.044"},{"issue":"2","key":"e_1_2_8_8_1","first-page":"CD003244","article-title":"Medical treatments in the short term management of reflux oesophagitis","author":"Khan M","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.08.014"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03451.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.200063"},{"key":"e_1_2_8_12_1","first-page":"41","article-title":"Quality of life in reflux and dyspepsia patients. psychometric documentation of a new disease\u2010specific questionnaire (QOLRAD)","volume":"583","author":"Wiklund IK","year":"1998","journal-title":"Eur J Surg Suppl"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.022"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.146"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304883"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12298"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.447"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510011579"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12877","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:06:25Z","timestamp":1695539185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,15]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/apt.12877"],"URL":"https:\/\/doi.org\/10.1111\/apt.12877","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,15]]}}}